Wednesday, October 21, 2020 Daily Archives

Evaluation Of a New Glucose Control Strategy Using CITSens Bio APC (Automated Process Control) for CHO Fed-Batch Application

by

For the cultivation of cells in research and development, high cell densities and reproducibility are fundamental aims. For that goal a high degree of automation is favorable to reduce the risk of contamination and deviation between batches. As glucose is one of the main energy sources for cells, it is crucial to maintain a constant and controlled automated glucose supply. Therefore, the CITSens Bio APC a combined system to measure and control the glucose concentration in cell culture applications was…

October 21, 2020

Webcast: Enabling Digital Chromatogram Review for a Faster and More Reliable Operation

by

This webcast features: Martin D. Jensen, Senior Engineer, FUJIFILM Diosynth Biotechnologies Chromatogram review is a monitoring method used to verify process performance in packed-bed chromatography processes. By observing key process parameters such as chromatography column outlet conductivity or UV absorbance, it is possible to identify the signs of a poorly packed column, resin degradation, or equipment malfunction. The industry standard practice relies on performing a paper-based qualitative visual comparison of chromatography profiles against a reference batch. This approach leads to a…

October 21, 2020

EMA committee nod for Orchard’s Libmeldy positive for AGC Biologics

by

AGC Biologics looks set to start making Orchard Therapeutics’ Libmeldy after an EMA panel recommended the gene therapy be approved. The agency’s the Committee for Medicinal Products for Human Use (CHMP) recommended approval last week, explaining Libmeldy (cryopreserved autologous CD34+ cells encoding the arylsulfatase-A, or ARSA, gene) slows down progression of the lysosomal storage disease, metachromatic leukodystrophy (MLD). Orchard CEO Bobby Gaspar welcomed the recommendation. He said it “brings us closer to delivering a one-time, potentially transformative therapy for eligible…

October 21, 2020

Swiss plant demonstrates synergies of KBI and Selexis acquisitions for JSR

by

A facility in Geneva will be home to two of JSR Life Sciences acquisitions offering customers both cell line development and drug substance manufacturing. Financial details of the new facility, occupying 8,700 square meters in the Stellar 32 campus in Geneva, Switzerland, have not been divulged, but will house both biologics manufacturer KBI Biopharma and cell line developer Selexis. Both companies are owned by JSR Life Sciences, a California-headquartered firm which has been upping its presence in the bioprocess space…

October 21, 2020

Fallen in place: Lonza veteran to lead Touchlight

by

Touchlight hires Lonza’s Karen Fallen as CEO of its contract manufacturing organization, Touchlight DNA Services. Fallen joins Touchlight from Lonza, where she began working after the latter company’s acquisition of Celltech in 1996. By the end of her time at Lonza, Fallen held the position of head of mammalian & microbial development & manufacturing, where she was responsible for a workforce of 4,500 individuals, spanning 10 different sites. Fallen’s new organization is Touchlight DNA Services, based in Hampton, UK, which…

October 21, 2020